Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment
Zaker Schwabkey(The University of Texas MD Anderson Cancer Center), Samer A. Srour(The University of Texas MD Anderson Cancer Center), Tomo Hayase(The University of Texas MD Anderson Cancer Center), Ivonne I. Flores(The University of Texas MD Anderson Cancer Center), Diana H. Wiesnoski(The University of Texas MD Anderson Cancer Center), Lin Tan(University of South Carolina), Tyler P. Graf(Rice University), Yusuke Shono(Memorial Sloan Kettering Cancer Center), Rawan K. El-Himri(The University of Texas MD Anderson Cancer Center), Gabriela Rondón(The University of Texas MD Anderson Cancer Center), Rishika Prasad(The University of Texas MD Anderson Cancer Center), Mathilde Raybaud(The University of Texas MD Anderson Cancer Center), Nadim J. Ajami(Baylor College of Medicine), Raphael H. Valdivia(Duke University), Marina Burgos da Silva(Cornell University), Eiko Hayase(Hokkaido University), Marc O. Warmoes(The University of Texas MD Anderson Cancer Center), Jennifer A. Wargo(The University of Texas MD Anderson Cancer Center), Jonathan U. Peled(Memorial Sloan Kettering Cancer Center), Stephanie Fowler, Taylor M. Halsey(The University of Texas MD Anderson Cancer Center), Miriam R. Ortega Turrubiates(The University of Texas MD Anderson Cancer Center), Brooke E. Heckel(The University of Texas MD Anderson Cancer Center), Lauren McDaniel(The University of Texas MD Anderson Cancer Center), Alexandria Brown(The University of Texas MD Anderson Cancer Center), Takahiko Miyama(The University of Texas MD Anderson Cancer Center), V. Behrana Jensen(The University of Texas MD Anderson Cancer Center), Alton G. Swennes(Massachusetts Institute of Technology), Saira Ahmed(The University of Texas MD Anderson Cancer Center), Christopher A. Sanchez(The University of Texas MD Anderson Cancer Center), Jessica Galloway-Peña(The University of Texas MD Anderson Cancer Center), Philip L. Lorenzi(The University of Texas MD Anderson Cancer Center), Yimei Jin(The University of Texas MD Anderson Cancer Center), Kevin J. McHugh(Texas Oncology), Yushu Shi(The University of Texas MD Anderson Cancer Center), Lauren Davey(University of Victoria), Dung Pham(The University of Texas MD Anderson Cancer Center), Carrie R. Daniel(The University of Texas MD Anderson Cancer Center), Pavan Reddy(University of Michigan), Chia‐Chi Chang(The University of Texas MD Anderson Cancer Center), Pablo C. Okhuysen(The University of Texas MD Anderson Cancer Center), Wen-Bin Tsai(The University of Texas MD Anderson Cancer Center), Annette C. Frenk Oquendo(The University of Texas MD Anderson Cancer Center), Valerie Chapa(The University of Texas MD Anderson Cancer Center), Christine B. Peterson(The University of Texas MD Anderson Cancer Center), Liangliang Zhang(The University of Texas MD Anderson Cancer Center), Yinghong Wang(The University of Texas MD Anderson Cancer Center), Margaret E. Conner(Baylor College of Medicine), Kim‐Anh Do(Cancer Research And Biostatistics), Marcel R.M. van den Brink(Memorial Sloan Kettering Cancer Center)
Cited by 58
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
|Cell|2018|2k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k